ICON Public Limited Company Stock (NASDAQ:ICLR)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$204.61

52W Range

$183.38 - $347.72

50D Avg

$228.65

200D Avg

$293.69

Market Cap

$17.13B

Avg Vol (3M)

$1.31M

Beta

1.25

Div Yield

-

ICLR Company Profile


ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.

Show More

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IE

Employees

42,250

IPO Date

May 15, 1998

Website

ICLR Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
IRELAND$2.38B$1.98B$1.37B
Other Countries$884.50M$563.86M$358.39M
Rest Of Europe$1.57B$1.62B$1.18B
UNITED STATES$3.28B$3.57B$2.58B

Fiscal year ends in Dec 23 | Currency in USD

ICLR Financial Summary


Dec 23Dec 22Dec 21
Revenue$8.12B$7.74B$5.48B
Operating Income$1.06B$795.24M$608.47M
Net Income$612.34M$505.30M$153.19M
EBITDA$1.69B$1.44B$923.46M
Basic EPS$7.40$6.20$2.28
Diluted EPS$7.40$6.13$2.25

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Oct 24, 24 | 11:39 AM
Q2 24Jul 25, 24 | 3:10 PM
Q1 24Apr 25, 24 | 12:00 AM

Peer Comparison


TickerCompany
TWSTTwist Bioscience Corporation
QGENQiagen N.V.
MTDMettler-Toledo International Inc.
IQVIQVIA Holdings Inc.
LHLaboratory Corporation of America Holdings
NEOGNeogen Corporation
MEDPMedpace Holdings, Inc.
CRLCharles River Laboratories International, Inc.
WATWaters Corporation